Barrington Research Reaffirms Outperform Rating for HealthEquity (NASDAQ:HQY)

HealthEquity (NASDAQ:HQY)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Barrington Research in a research note issued on Friday,Benzinga reports. They presently have a $112.00 price target on the stock. Barrington Research’s target price would suggest a potential upside of 36.25% from the stock’s current price.

A number of other analysts have also recently weighed in on HQY. The Goldman Sachs Group lowered their target price on shares of HealthEquity from $107.00 to $94.00 and set a “neutral” rating on the stock in a research note on Thursday, March 27th. KeyCorp cut their price objective on HealthEquity from $120.00 to $110.00 and set an “overweight” rating for the company in a research report on Monday, March 24th. Wells Fargo & Company upped their target price on shares of HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Raymond James raised shares of HealthEquity from an “outperform” rating to a “strong-buy” rating and decreased their price target for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, HealthEquity presently has a consensus rating of “Buy” and an average price target of $112.58.

HealthEquity Stock Up 2.8 %

Shares of HQY stock opened at $82.20 on Friday. HealthEquity has a one year low of $65.01 and a one year high of $115.59. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The stock has a fifty day moving average price of $97.63 and a 200 day moving average price of $96.30. The stock has a market cap of $7.11 billion, a P/E ratio of 75.41, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49.

Insider Buying and Selling at HealthEquity

In related news, EVP Michael Henry Fiore sold 8,881 shares of the firm’s stock in a transaction on Friday, April 4th. The stock was sold at an average price of $78.26, for a total transaction of $695,027.06. Following the sale, the executive vice president now owns 56,655 shares of the company’s stock, valued at approximately $4,433,820.30. This trade represents a 13.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Robert W. Selander sold 5,750 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $111.29, for a total transaction of $639,917.50. Following the sale, the director now owns 78,219 shares in the company, valued at $8,704,992.51. This trade represents a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,381 shares of company stock worth $1,781,432. Insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On HealthEquity

Several institutional investors have recently bought and sold shares of HQY. Congress Asset Management Co. increased its stake in HealthEquity by 168.0% in the 1st quarter. Congress Asset Management Co. now owns 68,253 shares of the company’s stock valued at $6,032,000 after buying an additional 42,785 shares during the last quarter. Radnor Capital Management LLC grew its holdings in shares of HealthEquity by 6.2% in the 1st quarter. Radnor Capital Management LLC now owns 6,040 shares of the company’s stock valued at $534,000 after acquiring an additional 350 shares in the last quarter. Chesley Taft & Associates LLC increased its position in shares of HealthEquity by 44.7% in the first quarter. Chesley Taft & Associates LLC now owns 12,622 shares of the company’s stock valued at $1,115,000 after acquiring an additional 3,897 shares during the last quarter. Portside Wealth Group LLC acquired a new position in HealthEquity during the first quarter valued at approximately $225,000. Finally, Hennion & Walsh Asset Management Inc. grew its stake in HealthEquity by 40.0% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 3,137 shares of the company’s stock valued at $277,000 after purchasing an additional 897 shares in the last quarter. Institutional investors own 99.55% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.